Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 10.01 ($0.13) and traded as high as GBX 10.25 ($0.14). Scancell shares last traded at GBX 10 ($0.13), with a volume of 409,111 shares traded.
Scancell Trading Down 4.1%
The business's 50 day moving average price is GBX 10.11 and its two-hundred day moving average price is GBX 9.65. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company has a market capitalization of £97.10 million, a price-to-earnings ratio of -14.37 and a beta of 0.35.
Insider Activity
In other news, insider Martin Diggle acquired 44,944 shares of the stock in a transaction on Tuesday, May 20th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,447.02). Insiders own 4.96% of the company's stock.
Scancell Company Profile
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
See Also
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.